cetuximab-Zr-89

Cetuximab-Zr-89 is a radioimmunoconjugate consisting of the recombinant chimeric monoclonal antibody cetuximab labeled with the positron-emitting radioisotope zirconium-89 (Zr-89). Cetuximab targets and binds to the epidermal growth factor receptor (EGFR), which is overexpressed in various cancers. The radiolabeled antibody enables noninvasive PET imaging to assess EGFR expression and drug accessibility in tumors. This agent is primarily used as a molecular imaging tool for patient selection and monitoring response or resistance to anti-EGFR therapy in cancers such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (mCRC)[1][2][3][7][10]. It provides additional information beyond standard FDG-PET by visualizing actual drug delivery to tumor tissue.

Other names

cetuximab-Zr-89cetuximab-Zr89cetuximab-Zr 89zirconium Zr 89-cetuximab89Zr-cetuximab89Zr-DFO-cetuximab